Enclomiphene citrate 是口服具有活力的oestrogen receptor拮抗剂，具有抗雌激素活性。

Enclomiphene citrate is a non-steroidal estrogen receptor antagonist,with antioestrogenic property

total testosterone (TT) levels increased between baseline and after 16 weeks of treatment in all the treatment groups. FSH and LH levels increased in the enclomiphene citrate groups and decreased in the testosterone gel group at 16 weeks. Enclomiphene citrate maintained sperm concentration in the normal range over the treatment period, while there was a marked reduction in spermatogenesis in the testosterone gel group[1].

Two parallel randomised, double-blind, double-dummy, placebo-controlled, multicentre, phase III studies were undertaken to evaluate two doses of enclomiphene citrate vs testosterone gel on total testosterone (TT), LH, FSH, and sperm counts in overweight men aged 18-60 years with secondary hypogonadism. Men were screened and enrolled in the trials (ZA-304 and ZA-305). All enrolled men had early morning serum TT levels in the low or low normal range (≤300 ng/dL; ≤10.4 nmol/L) and had low or normal LH (<9.4 IU/L) levels measured on two separate occasions 2-10 days apart. Serum samples were obtained over the course of the study to determine relevant hormone levels at baseline and after 16 weeks of treatment. Men provided semen samples twice to enroll at the beginning and twice at the end of the study[1].

7599-79-3

C32H36ClNO8

598.09

(E)-Clomiphene citrate;trans-Clomiphene citrate;Enclomifene citrate;恩氯米芬柠檬酸盐

DMSO:50 mg/mL (83.60 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years